Join Growin Stock Community!

Rein therapeutics inc.RNTX.US Overview

US StockHealthcare
(No presentation for RNTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RNTX AI Insights

RNTX Overall Performance

RNTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RNTX Recent Performance

7.46%

Rein therapeutics inc.

0.05%

Avg of Sector

-0.31%

S&P500

RNTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RNTX Key Information

RNTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RNTX Profile

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Price of RNTX

RNTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RNTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
25.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
25.51
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is RNTX's latest earnings report released?

    The most recent financial report for Rein therapeutics inc. (RNTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RNTX's short-term business performance and financial health. For the latest updates on RNTX's earnings releases, visit this page regularly.

  • How much cash does RNTX have?

    At the end of the period, Rein therapeutics inc. (RNTX) held Total Cash and Cash Equivalents of 4.05M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RNTX's EPS continuing to grow?

    According to the past four quarterly reports, Rein therapeutics inc. (RNTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.21. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RNTX?

    Rein therapeutics inc. (RNTX)'s Free Cash Flow (FCF) for the period is -3.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 7.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.